Tailoring antiviral therapy in hepatitis C

Hepatology

Volumn 43, Issue 5, 2006, Pages 909-911

  Davis, Gary L ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; PEGINTERFERON; RIBAVIRIN; VIRUS RNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; DOSE RESPONSE; DRUG HALF LIFE; EDITORIAL; GENOTYPE; HEPATITIS C; HUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; HEPACIVIRUS; HEPATITIS C; HUMANS;

EID: 33646572206     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21194     Document Type: Editorial

References (18)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized controlled study. N Engl J Med 1989;321:1501-1506.
2. Shindo M, Di Bisceglie AM, Cheung L, Shih JW, Cristiano K, Feinstone SM, et al. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for hepatitis C. Ann Intern Med 1991; 115:700-704.
3. Yokosuka O, Kato N, Hosoda K, Ito Y, Imazeki F, Ohio M, et al. Efficacy of longterm interferon treatment in chronic liver disease evaluated by sensitive polymerase chain reaction assay for hepatitis C virus RNA. Gut 1995;37:721-726.
4. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492.
5. Poynard T, Marcellin P, Lee S, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432.
6. Manns MP, McHutchison JG, Gordon S, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alpha-2b plus ribavirin compared to interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C: a randomized trial. Lancet 2001;358:958-965.
7. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
8. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-355.
9. Davis GL, Wong JB, McHutchison JG, Manns MP, Albrecht J. Early virologic response to treatment with pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C. HEPATOLOGY 2003; 38:645-652.
10. T Berg, M von Wagner, H Hinrichsen, et al. Reduction of the relative relapse rate by prolongation of the duration of a therapy with peginterferon alfa-2a plus ribavirin in patients with genotype 1 infection up to 72 weeks [Abstract]. HEPATOLOGY 2004;40(Suppl):238A.
11. JM Sanchez-Tapias, M Diago, P Escartin, et al. Longer treatment duration with peginterferon Alfa-2a (40KD) (Pegasys®) and ribavirin (Copegus®) in naïve patients with chronic hepatitis C and detectable HCV RNA by week 4 of therapy: final results of the randomized, multicenter TERAVIC-4 study [Aabstract]. HEPATOLOGY 2004;40(Suppl):218A.
12. Gross J, Johnson S, Kwo P, Afdhal N, Flamm S, Therneau T. Double-dose peginterferon alfa-2b with weight-based ribavirin improves response for interferon/ribavirin non-responders with hepatitis C: final results of "RENEW" [Abstract]. HEPATOLOGY 2005;42(Suppl 1):219A.
13. Shiffman ML, Price A, Hubbard S, Wilson M, Salvatori J, Sterling R, et al. Treatment of chronic hepatitis C virus (HCV) genotype 1 with peginterferon alfa-2b (PEGIFN), high weight based dose ribavirin (RVN) and epoetin alfa (EPO) enhances sustained virologic response (SVR) [Abstract]. HEPATOLOGY 2005;42(Suppl 1):217A.
14. Dalgard O, Bjoro K, Helium KB, Myrvang B, Ritland S, Skaug K, et al. Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. HEPATOLOGY 2004;40:1260-1265.
15. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-2617.
16. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, et al. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005;129:522-527.
17. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsman Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
18. Jensen DM, Morgan TR, Marcellin P, Pockrus PJ, Reddy KR, Hadziyannis S, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a(40 kd)/ribavirin therapy. HEPATOLOGY 2006;43:954-960.